Brazil: ANVISA Approval and Public Health System Access
Brazil's ANVISA regulates GLP-1 drugs nationally, with access shaped by both the public SUS health system and a large private insurance market.
By the GLP Semaglutide editorial team · Last updated January 22, 2026
Brazil's Agência Nacional de Vigilância Sanitária (ANVISA) is the national regulator responsible for drug approval and market authorization, including GLP-1 receptor agonists sold in Brazil.
Two parallel access systems
Brazil's universal public health system (SUS) and a substantial private insurance and out-of-pocket market operate in parallel, and GLP-1 drug access and cost can differ significantly depending on which system a patient relies on and whether a specific indication is included in public formularies.
Where to verify
ANVISA's public database lists approved products, and Brazil's Ministry of Health publishes SUS formulary and coverage decisions directly — the authoritative sources rather than secondary market reporting.
Primary sources